Francisella tularensis, which causes tularemia, is an intracellular gram-negative bacterium. F. tularensis has received significant attention in recent decades because of its history as a biological weapon. Thus, development of novel vaccines against tularemia has been an important goal. The attenuated F. tularensis strain DpdpC, in which the pathogenicity determinant protein C gene (pdpC) has been disrupted by TargeTron mutagenesis, was investigated as a potential vaccine candidate for tularemia in the present study. C57BL/6J mice immunized s.c. with 1 Â 10 6 CFUs of DpdpC were challenged intranasally with 100Â the median lethal dose (LD 50 ) of a virulent SCHU P9 strain 21 days post immunization. Protection against this challenge was achieved in 38% of immunized C57BL/6J mice administered 100 LD 50 of this strain. Conversely, all unimmunized mice succumbed to death 6 days post challenge. Survival rates were significantly higher in vaccinated than in unimmunized mice. In addition, DpdpC was passaged serially in mice to confirm its stable attenuation. Low bacterial loads persisted in mouse spleens during the first to tenth passages. No statistically significant changes in the number of CFUs were observed during in vivo passage of DpdpC. The inserted intron sequences for disrupting pdpC were completely maintained even after the tenth passage in mice. Considering the stable attenuation and intron sequences, it is suggested that DpdpC is a promising tularemia vaccine candidate.
Various approaches to developing a tularemia vaccine for prevention of tularemia have been tried (7) . An LVS derived from multiple passages of a virulent strain of F. tularensis subspecies holarctica has been investigated as a possible new drug in the USA (8) . However, this vaccine does not confer strong protection against respiratory challenge with F. tularensis and has not been licensed (9, 10) . In addition, under some conditions culture of live vaccine strains can result in emergence of poorly immunogenic variants (11) . Other variant strains with low pathogenicity have recently been developed as vaccines against tularemia (12) (13) (14) .
Proteins encoded by genes on the Francisella pathogenicity island have been demonstrated to play critical roles in the unique intracellular behavior of this bacterium (15) (16) (17) . Pathogenicity determinant protein C (pdpC) is one of the genes within the Francisella pathogenicity island. DpdpC, in which pdpC has been disrupted by TargeTron mutagenesis, exhibits a different phenotype (18) (19) (20) . In our previous study, we reported that PdpC is crucial in determining the virulence of F. tularensis SCHU P9 because DpdpC displays significantly decreased intracellular growth in J774.1 cells and does not induce severe disease in experimentally infected mice (21) . Further, the virulence of DpdpC was restored via complementation with a protein expressed from a plasmid containing the intact pdpC gene (21) .
In this study, we investigated whether DpdpC could serve as a live attenuated tularemia vaccine candidate in a mouse model challenged by SCHU P9. In addition, we investigated the stability of attenuation of DpdpC after serial passage in mice.
MATERIALS AND METHODS

Ethics statement
Experiments involving animals were performed in strict accordance with the Animal Experimentation Guidelines of the National Institute of Infectious Diseases. The protocol was approved by the Institutional Animal Care and Use Committee of the National Institute of Infectious Diseases (Permission Numbers: 116046 and 215073).
Bacterial strains
F. tularensis strains SCHU P9 and DpdpC were established in our previous study (21) . They were cultured in CDM (21) at 37°C for 24 hr, suspended in CDM containing 10% glycerol, and stored at À80°C until use. All experiments with live bacterial cultures were performed in a Biosafety Level 3 facility in accordance with regulations stipulated by the National Institute of Infectious Diseases.
In tularemia research, the most investigated virulent F. tularensis subspecies tularensis strain is SCHU S4 strain (22) . Highly virulent strain SCHU S4 originated from a virulent SCHU strain that was originally isolated by Foshay in 1941 from a human finger ulcer (23) . The LD 50 of SCHU strain for mice, guinea pigs and rabbits have been shown to be less than 10 organisms on s.c. inoculation (24) . The virulent SCHU strain was supplied to Ohara Research Laboratory of Japan by Rocky Mountain Laboratory, National Institute of Allergy and Infectious Diseases (Hamilton, MT, USA) in 1958 (25) . When SCHU strain is extensively cultured on LGH agar, its virulence is attenuated; however, the virulence has been shown to recovered after serial passages in mice (25) . An SCHU strain kindly provided by Dr. H. Fujita (Ohara Research laboratory, Fukushima, Japan) was apparently attenuated because of extensive in vitro passages; a virulent strain was achieved after nine serial passages in mice (referred to as SCHU P9) in our laboratory (21) . In our previous study, the whole genome sequence of SCHU P9 was compared with that of SCHU S4, both these strains having originated from the same parental original SCHU strain, and 35 differences, including 29 single nucleotide mutations and six deletions/insertions, were found (21) . The LD 50 of SCHU P9 was 5 and 50 CFU upon i.p. and i.n. inoculation, respectively, indicating that the virulence of SCHU P9 is comparable to that of SCHU S4 (21) . In Japan, it is difficult to obtain SCHU S4 strain from foreign laboratories because transport of bacteria is highly regulated by Japanese infectious disease control laws. The SCHU P9 strain rather than SCHU S4 strain was therefore used as the virulent strain in the present study.
Animal experiments
Seven-week-old female C57BL/6J mice purchased from SLC (Shizuoka, Japan) were kept in an animal Biosafety Level 3 room with suitable temperature and humidity and a 12 hr/12 hr light-dark cycle. Different groups of mice housed in individual cages were provided ad libitum access to food and water. Mice were inoculated i.p. with bacteria under anesthesia induced by 3 mg of medetomidine hydrochloride (Domitor; Orion Diagnostica, Espoo, Finland), 40 mg of midazolam (Dormicum; Astellas Pharma, Tokyo, Japan), and 50 mg of butorphanol tartrate (Betorufaru; Meiji Seika Pharma, Tokyo, Japan). The mice were killed by inhalation of an overdose of isoflurane (Pfizer Japan, Tokyo, Japan).
Bacterial loads were quantified by inoculating 100 mL of homogenates of infected lungs, spleens and livers diluted in RPMI 1640 onto Eugon chocolate agar plates, as previously reported (21, 26) . After cultivation at 37°C for 4 days, CFUs were calculated by multiplying the average number of colonies by 10 to account for the dilution factor.
Immunization and challenge
Sixteen mice were immunized s.c. with 1 Â 10 6 CFUs/ 100 ml DpdpC, whereas eight mice were administered the same amount of saline as controls. All immunized mice were observed daily for clinical signs, and their body weights were recorded for 21 days after vaccination. Eight mice in the immunized group were killed by isoflurane inhalation to confirm residual bacterial counts. The control mice and remaining eight immunized mice were challenged with 100 LD 50 of SCHU P9 i.n. (left nostril) 21 dpi. The health of the animals was observed daily and moribund animals were killed. Surviving mice were killed 21 days after SCHU P9 challenge by isoflurane inhalation.
IgG antibody titers determined by ELISA
Blood samples were collected from the tail veins of immunized and control mice at 21 dpi and surviving mice 21 days after SCHU P9 challenge. Sera were obtained by centrifugation at 3500 g at 4°C for 10 min, incubated at 56°C for 30 min, and then inactivated by UV irradiation at 254 nm for 10 min.
Antibody titers were measured by ELISA as previously reported (27) . Briefly, SCHU P9 cultured on Eugon chocolate for 3 days was harvested, suspended in saline, adjusted to the concentration corresponding to an OD 600 of 1.0 and inactivated at 100°C for 10 min. The antigen was stored at À80°C until use. Heat-killed SCHU P9 antigen in 50 mM carbonate-bicarbonate buffer, pH 9.0 (100 mL/well) was added into the wells of a NuncImmuno plate (Thermo Scientific, Roskilde, Denmark), and the plates were left at 37°C overnight. After washing thrice with PBST to remove unbound antigen, all wells were blocked with 100 mL of PBST containing 3% skim milk at 37°C for 1 hr. After washing thrice with PBST, 50 mL of the serum samples diluted 1:100 in PBST containing 1% skim milk were added into antigencoated wells in duplicate and incubated at 37°C for 1.5 hr. After washing thrice with PBST, 50 mL of peroxidase-goat anti-mouse IgG (H þ L) (Invitrogen, Frederick, MD, USA) diluted to 1:10,000 was added into each well, after which the plates were incubated at 37°C for 1 hr. The wells were then washed thrice with PBST and developed with 100 mL of 2,2 0 -azino-bis (3-ethylbenzothiazoline-6-sulphonic acid) ELISA HRP substrate (Roche, Mannheim, Germany) at 37°C for 30 min. The OD 405 was measured in the each well using a BioRad 96-well plate reader (iMark; Bio-Rad Laboratories, Hercules, CA, USA).
Serum IFN-g concentrations
IFN-g concentrations in sera from unimmunized and immunized mice at 0 day and 3 dpc were measured using a FlowCytomix mouse Th1/Th2 10plex bead kit (eBioscience, Vienna, Austria) in accordance with the instruction manual. Data were acquired by FACS Canto II (Becton-Dickinson, Franklin Lakes, NJ, USA) and analyzed by FlowCytomix Pro 2.2 Software (Bender MedSystems GmbH, Vienna, Austria).
Genetic stability of DpdpC after in vivo passages
DpdpC was serially passaged in mice to determine its pathological and nucleic stability. Three mice were inoculated via an i.p. route with 1 Â 10 6 CFUs of DpdpC. Three days after inoculation, spleens were collected after killing the mice. Serial dilutions of spleen homogenates were then incubated on chocolate Eugon agar plates at 37°C for 3-4 days. CFUs were calculated by multiplying the average number of colonies by 10 to account for the dilution factor.
For the serial passages, 1 mL aliquots of 10% splenic homogenates were spread onto Eugon agar plates and cultured at 37°C for 2 days. After culture, bacteria were suspended in CDM and the concentration adjusted to approximately 1 Â 10 9 CFUs/mL. Bacterial suspensions containing 1 Â 10 6 CFUs of bacteria were inoculated i.p. into three C57BL/6J mice. Subsequent passages were similarly performed until the tenth generation. Genomic DNA was extracted from these suspensions using SepaGene (Sanko Junyaku, Tokyo, Japan) according to the manufacturer's instructions.
PCR was performed in a 50 mL reaction mixture containing 1 U of KOD-Plus-Neo enzyme (Toyobo, Osaka, Japan), 1 Â PCR buffer, 0.02 mM dNTPs, 1.5 mM MgSO 4 , 0.5 mM of the primers (pdpC-336s, 5 0 -ACT ATG GGG ATT AGT TGA TTT CGT-3 0 ; and pdpC725a, 5 0 -TGT TGT AAT CTT GGA GCT GCT T-3 0 ) and 10 ng of bacterial genomic DNA in each reaction. The reaction conditions were as follows: initial denaturation at 94°C for 2 min; 30 cycles of denaturation at 94°C for 0.5 min, annealing at 58°C for 0.5 min, extension at 68°C for 0.5 min and a final extension at 72°C for 7 min. PCR products were electrophoresed on a 1% agarose gel. Amplicons were treated with Illustra ExoProStar (GE Healthcare, Buckinghamshire, UK) to remove unincorporated primers and nucleotides according to the manufacturer's instructions. The nucleotide sequences of the amplicons were then determined by Eurofins Genomics (Tokyo, Japan).
Statistical analysis
All statistical analyses were performed using GraphPad Prism v5. Results are expressed as the mean AE SD. Between-group comparisons of IgG antibody titers were performed using two-way anova with Tukey-Kramer's multiple comparisons post-test. Survival rates were analyzed using the log-rank test and P values determined. Differences between the experimental groups were considered statistically significant at P < 0.001. CFUs in the spleens of mice infected with DpdpC at 3 days dpi were statistically analyzed using linear regression analysis. Differences in serum IFN-g concentrations were analyzed by anova with Tukey's posttest ( ÃÃ , P < 0.01).
RESULTS
Humoral immune responses in DpdpC-immunized mice
Blood samples were collected from the tail veins of C57BL/6J mice (n ¼ 8) at 21 dpi and of surviving mice at 21 days after SCHU P9 challenge. IgG antibody responses against F. tularensis in the immunized mice were determined by IgG-ELISA (Fig. 1) . The cut-off for OD in the ELISA was set at 0.390, which was defined as the average OD (0.158) in eight na€ ıve mice plus 3 Â SD (3 Â 0.077). In immunized mice, the average OD and SD at 3 weeks after immunization were 0.945 and 0.247, respectively, indicating that immunization had induced humoral immune responses in the mice. Upon challenge with virulent SCHU P9 strain, all eight na€ ıve mice died, whereas three of eight immunized mice survived (described below). The average OD and SD in the ELISA were 1.903 and 0.119, respectively, in the surviving mice. These data suggest that DpdpC induces IgG antibody responses against F. tularensis after s.c. immunization.
Protection against a lethal challenge of SCHU P9 in mice immunized with DpdpC
Whether mice immunized with DpdpC were effectively protected against a lethal challenge with SCHU P9 was investigated. Sixteen mice in each group were immunized s.c. with 1 Â 10 6 CFUs of DpdpC and half the mice in each group were killed and tested for residual bacteria. Immunization induced no obvious behavioral changes or clinical sign in the mice. No live bacteria were recovered from the blood, lungs, spleens or livers of mice inoculated with DpdpC at 21 dpi (data not shown). Thus, DpdpC is cleared in mice shortly after inoculation, indicating that immunization with 1 Â 10 6 CFUs of DpdpC is safe for mice.
At 21 dpi with DpdpC, the mice were challenged i.n. with 100 LD 50 of SCHU P9. Mice exhibiting serious clinical symptoms and >25% weight loss within 21 dpc were killed. All unimmunized mice had died or been killed within 6 dpc (Fig. 2) . The survival rate of immunized mice was 38% (Fig. 2) , this being significantly higher than for the unimmunized mice.
Cellular immune response in immunized mice
Serum IFN-g concentrations were determined to evaluate Th1 cellular immune responses in the immunized and unimmunized mice. Compared with 0 dpc, IFN-g was induced in all mice at 3 dpc with virulent SCHU P9. However, the difference in serum IFN-g concentrations between the immunized and unimmunized mice at 3 dpc Blood samples were collected from the tail veins of na€ ıve C57BL/6J mice (n ¼ 8) (circle) at 21 dpi (squares) and three surviving mice at 21 days after SCHU P9 challenge (triangles). Amounts of serum IgG antibody against F. tularensis were determined by ELISA at a serum dilution of 1:100. Mean AE SD of IgG titers are shown. The cut-off for OD in the ELISA was set at 0.390, which was defined as the average OD (0.158) in eight na€ ıve mice plus 3 Â SD (3 Â 0.077). Statistical significance was determined by two-way anova with Tukey's post-hoc tests ( ÃÃÃ , P < 0.001).
was not significant (Fig. 3) . Similarly, granzyme B, which is specifically expressed in functional cytotoxic T lymphocytes and NK cells, was rarely detected in immunized or unimmunized mice at 3 dpc by immunohistochemistry analysis (data not shown). These findings suggest that no prominent Th1 cellular immune response was induced by DpdpC immunization in mice.
Genetic stability of DpdpC after serial passages in mice
Genetic stability of the genes responsible for attenuation of live attenuated vaccines is crucial for their safety. Because a virulent SCHU P9 strain was easily isolated from an attenuated SCHU strain via serial passages in mice in our previous study (21) , it was important to determine whether the intron sequence introduced into DpdpC was stably maintained after serial passages in mice. Three mice were first inoculated i.p. with approximately 1 Â 10 6 CFUs of DpdpC (Fig. 4a) . Spleens collected from the mice at 3 dpi were homogenized and their CFUs determined (Fig. 4b) . In a previous study, mice inoculated with 1 Â 10 6 CFU of SCHU P9 had an average bacterial load in the spleen at 3 dpi of approximately 1 Â 10 8 CFUs/10 mg (21). The average bacterial burden in the mouse spleens during the first to tenth passages of DpdpC in this study was less than 1 Â 10 6 CFUs/10 mg, which was significantly lower than in the mice infected with SCHU P9. No significant changes in splenic bacterial loads were found during the first and tenth in vivo passages in mice infected with DpdpC by linear regression analysis using Prism software (Fig. 4b) .
Genomic DNA was extracted from DpdpC obtained after the first, fifth and tenth in vivo passages. The partial sequence containing the intron was then amplified using the pdpC-336s/pdpC-725a primer pair to confirm the genetic stability of the intron sequences (Fig. 4) . Genomic DNA extracted from DpdpC and SCHU P9 was used as controls for PCR. The expected sizes of amplicons with and without intron sequences in pdpC were 1305 and 309 bp, respectively (Fig. 4c) . It was confirmed that DpdpC constantly harbored the intron after the first, fifth and tenth passages (Fig. 4c) . In addition, no nucleotide substitutions or deletions/ insertions in the intron sequences were detected after the tenth passage (data not shown). These findings . Statistical significance of differences in survival rate was determined using the log-rank (Mantel-Cox) test ( ÃÃÃ , P < 0.001). CFUs of DpdpC or saline. At 21 dpi, the mice were challenged i.n. with 100 LD 50 of SCHU P9. IFN-g concentrations in sera collected from the immunized and unimmunized mice at 0 and 3 dpc were measured. Mean AE SD of serum IFN-g concentrations are shown. Statistical significance was determined by one-way anova with Tukey's post-test ( ÃÃ P < 0.01).
indicate that the intron inserted in pdpC was stable. It was therefore concluded that DpdpC is a safe and immunogenic tularemia vaccine candidate suitable for further clinical development.
DISCUSSION
Because F. tularensis is a highly infectious bacterium that has the potential to be used as a biological weapon, an Spleen samples from the three mice were processed as described in the text. The inoculation dose and CFU in the spleen at 3 dpi in each passage are shown in the top table. (b) Bacterial burden in the spleen. One hundred microliters of 10 fold serial diluted homogenates were inoculated on chocolate Eugon agar in 6-well plates. After incubation for 4 days, numbers of colonies were counted. Differences in CFU in the spleens from mice inoculated with each passage of the DpdpC were analyzed by the linear regression method and found to not differ significantly. (c) Genetic stability of the intron sequences in DpdpC during serial passages in mice. Genomic DNAs extracted from DpdpC, SCHU P9, and passaged bacteria (first, fifth and tenth) were amplified by PCR using pdpC336s and pdpC725a primer pair (upper panel). The amplicons and a molecular weight marker of Smart Ladder (0.2-10 kbp; Nippongene, Tokyo, Japan) were electrophoresed on a 0.7% agarose gel. The predicted sizes of amplicons with and without intron are 1305 bp and 390 bp, respectively (lower panel).
effective vaccine needs to be developed (5, 28, 29) . Attempts to develop a vaccine against tularemia have employed several different strategies. The earliest viable vaccine against tularemia was a killed tularemia vaccine produced by Lee Foshay in 1930 (30) . When tested in human volunteers, this vaccine was shown to provide protection against intracutaneous challenge with SCHU S4 but did not provide protection against respiratory challenge (31, 32) . Because of the limitations of the killed vaccine, F. tularensis subsp. holarctica LVS was developed in the 1960s and used in human volunteers (8, 33) . This LVS was observed to provide partial protection against challenge with F. tularensis type A strain in humans (34) . Researched on LVS is ongoing (11, 35) ; however, this live vaccine strain is not available for public use because it is not licensed in the USA or other countries, primarily because of uncertainty regarding its source of attenuation and instability in culture (8, 36, 37) . Thus, investigation of a novel vaccine against tularemia has remained a critical research goal in recent years, the aim being to develop a fully protective attenuated vaccine for which safety concerns have been eliminated or further minimized. Numerous live attenuated mutants derived from LVS and the virulent Schu S4 strain have been developed (9, 36) . In our previous study (21), we obtained a virulent strain, SCHU P9, from a SCHU strain, from which we selected SCHU S4 (22, 25) . SCHU P9 has been shown to be highly virulent, comparable to SCHU S4, in mice (38, 39) . In this study, we used SCHU P9 as a challenge strain after immunization because of difficulty in obtaining the SCHU S4 strain from foreign laboratories, transport of this bacterium being highly regulated by Japanese infectious disease control laws.
Mutant SCHU P9, DpdpC, which was generated by group II intron insertion using a TargeTron gene knockout system (Sigma-Aldrich) and the pKEK1140 plasmid (GenBank accession number: EU499313) (40) from the virulent SCHU P9 strain, did not induce any clinical signs in infected mice. Thus, we speculate that DpdpC had potential as a novel live vaccine strain. In this study, we immunized mice s.c. with DpdpC and challenged them with i.n. SCHU P9.
We found that 38% of immunized mice survived challenge with the virulent strain, whereas all unimmunized mice died (Fig. 2) . The survival rates were significantly higher in the immunized (log-rank test analysis) than that the unimmunized group (Fig. 2a) .
In addition, we demonstrated the genetic stability of the intron sequences in DpdpC during in vivo passage and, after the tenth passage, detected a small bacterial burden in the spleens of mice infected with DpdpC (Fig. 4b) . This evidence supports the contention that DpdpC elicits protective immunity and that the strain is safe, indicating its suitability as a candidate live attenuated vaccine against F. tularensis.
It has been reported that antibodies against F. tularensis may offer a considerable survival advantage in patients with respiratory tularemia because these antibodies have been shown to inhibit bacterial spread from the lungs to other organs (41, 42) . However, 100% protection against F. tularensis type A strains via vaccination has been difficult to achieve (36) . Recent reports indicate that antibodies contribute to protection against F. tularensis LVS (Type B) challenge, but the importance of antibodies to F. tularensis Schu S4 (Type A) challenge is more controversial (36) . In this study, antibody responses against F. tularensis were well established in mice immunized s.c. with DpdpC (Fig. 1) .
It is well known that cellular immunity also plays an important role in protection against intracellular bacterial infections (43). Hence, we investigated induction of functional cellular immunity in immunized and unimmunized mice after challenge with virulent SCHU P9. Concentrations of IFN-g, which is indispensable for differentiation of Th1 cells, were measured in mouse sera. In addition, at 3 dpc various tissues were immunohistochemically stained with polyclonal antibodies against granzyme B, which is known to be expressed specifically in cytotoxic T lymphocytes and NK cells (44) . We detected no significant differences in serum IFN-g concentrations in immunized and unimmunized mice at 3 dpc with SCHU P9 (Fig. 3) or in the numbers of granzyme B positive cells in tissues such as liver and spleen (data not shown). Thus, we were unable to confirm cellular immunity to protect against lethal challenge by virulent SCHU P9 in immunized mice in this study. However, it appears clear that synergy between humoral and cellular immunity is an important factor in protection against F. tularensis (45, 46). The survival rate of immunized mice may improve if the cellular immunity was induced more strongly than in this study.
C57BL/6 and BALB/c mice are often used as animal models of tularemia as well as for studies on F. tularensis vaccine development. The genetic background of individual strains of mice often significantly affects the immune response and survival rates in murine models of infectious diseases and vaccination (36, (47) (48) (49) . It is known that C57BL/6 mice are more susceptible to F. tularensis infection and that they exhibit more severe symptoms of tularemia than BALB/c mice (36) . Thus, the survival rates may be better if BALB/c mice are used.
Researchers are attempting to develop safe and effective immunization with attenuated tularemia vaccines. Death following challenge with more than 100 CFUs of Schu S4 has reportedly been prevented in mice immunized with attenuated strains derived from types A (DclpB [48] , DcapB [50] , DFTT_0918 [51] and Dggt [52] ) and B strains (DdsbA [53] and DsodB [54] ). In a recent report, Lindgren et al. showed that DpdpC confers protective immunity against intradermal challenge with Schu S4, but does not protect against i.n. challenge (18) . In the present study, our DpdpC conferred protective immunity against i.n. challenge with Schu P9. In a previous study, BALB/c mice were immunized intradermally, whereas C57BL/6J mice were immunized s.c.; thus, differences in protective immunity between these studies may be attributable to either mouse strain used or immunization route. These possibilities should be examined in future. Our finding that survival rates were significantly higher in the vaccinated than unimmunized mice also indicates that DpdpC can be used as a vaccine candidate (Fig. 2) . Taken together, induction of sterile immunity by vaccination against respiratory disease caused by virulent type A F. tularensis strains remains difficult if more than 100 CFUs of the bacteria are introduced.
We investigated risks associated with reversion of a live tularemia vaccine in recipients because attenuated F. tularensis strains often regain virulence during several passages in mice (21, 25, 55) . We demonstrated that attenuation in DpdpC was stably maintained after 10 serial passages in mice in this study (Fig. 4) . Based on these results, DpdpC is sufficiently attenuated to satisfy the requirements for a safe vaccine.
In conclusion, the attenuated DpdpC strain elicits protective immunity against lethal infection by SCHU P9 in mice, but does not protect all the mice. The inserted intron sequences used to disrupt pdpC genes using the TargeTron system are stably maintained during serial passage in mice. These data suggest that DpdpC is a safe and immunogenic tularemia vaccine candidate suitable for further clinical development.
